Encouraging Signs For Galapagos In CLL, But “Point-Of-Care CAR-T” Is Biggest Challenge

Early data suggests its CAR-T could crack the tough challenge in CLL – but developing an automated CAR-T production unit for local hospitals is likely to be Galapagos’s greatest test.

Galapagos is developing its point-of-care 'Cocoon' manufacturing system to bring CAR-T to many more patients globally.

In a crowded field, Galapagos needs to find a niche where its point-of-care CAR-T concept can shine – and believes chronic lymphocytic leukemia could be it.

The company hosted a key opinion leader webinar at the American Society of Hematology on 10 December to highlight updated results from its two lead CD19 CAR-Ts, GLPG5101 and GLPG5201.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Encouraging Signs For Galapagos In CLL, But “Point-Of-Care CAR-T” Is Biggest Challenge

Read the full article – start your free trial today!

More from Clinical Trials

More from R&D